Mohamad Shebley, Ph.D.
Affiliations: | 2007 | University of Michigan, Ann Arbor, Ann Arbor, MI |
Area:
PharmacologyGoogle:
"Mohamad Shebley"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Paul F. Hollenberg | grad student | 2007 | University of Michigan | |
| (Mechanism-based inactivation of human cytochrome P450 2B6 by phencyclidine: Metabolism, structural, and mechanistic studies.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Polepally AR, Ng JW, Salem AH, et al. (2020) Assessment of Clinical Drug-Drug Interactions of Elagolix, a Gonadotropin-Releasing Hormone Receptor Antagonist. Journal of Clinical Pharmacology |
| Chiney MS, Ng J, Gibbs JP, et al. (2019) Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling. Clinical Pharmacokinetics |
| Mukherjee D, Zha J, Menon RM, et al. (2018) Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model. Journal of Pharmacokinetics and Pharmacodynamics |
| Shebley M, Liu J, Kavetskaia O, et al. (2017) Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus 3-Direct Acting Antiviral (3D) Regimen: Paritaprevir/Ritonavir, Ombitasvir and Dasabuvir. Drug Metabolism and Disposition: the Biological Fate of Chemicals |
| Freise KJ, Shebley M, Salem AH. (2017) Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model. Journal of Clinical Pharmacology |
| Kikuchi R, Shebley M, Bow DAJ, et al. (2017) In vitro characterization of drug metabolizing enzymes and transporters to enable a mechanistic drug-drug interaction assessment for venetoclax Drug Metabolism and Pharmacokinetics. 32 |
| Einolf HJ, Chen L, Fahmi OA, et al. (2014) Evaluation of various static and dynamic modeling methods to predict clinical CYP3A induction using in vitro CYP3A4 mRNA induction data. Clinical Pharmacology and Therapeutics. 95: 179-88 |
| Shebley M, Kent UM, Ballou DP, et al. (2009) Mechanistic analysis of the inactivation of cytochrome P450 2B6 by phencyclidine: Effects on substrate binding, electron transfer, and uncoupling Drug Metabolism and Disposition. 37: 745-752 |
| Shebley M, Hollenberg PF. (2007) Mutation of a single residue (K262R) in P450 2B6 leads to loss of mechanism-based inactivation by phencyclidine. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 35: 1365-71 |
| Shebley M, Jushchyshyn MI, Hollenberg PF. (2006) Selective pathways for the metabolism of phencyclidine by cytochrome p450 2b enzymes: identification of electrophilic metabolites, glutathione, and N-acetyl cysteine adducts. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 34: 375-83 |